SciSparc announced the submission of a new patent application to the USPTO for a novel treatment combining Palmitoylethanolamide (PEA) from their CannAmide™ with Clearmind Medicine's MEAI compound, targeting metabolic syndrome and obesity. This application is part of an ongoing collaboration with Clearmind Medicine and Professor Joseph Tam from Hebrew University.The development addresses a significant market opportunity, as CDC data shows 41.9% of US adults aged 20 and over were obese during 2017-2020. The global obesity treatment market, valued at $15 billion in 2022, is projected to grow at a 10% CAGR, driven by increasing obesity prevalence and technological advancements.This marks the thirteenth patent application filed through the Clearmind collaboration, with previous applications covering treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders using the PEA-MEAI combination.

SciSparc announced the submission of a new patent application to the USPTO for a novel treatment combining Palmitoylethanolamide (PEA) from their CannAmide™ with Clearmind Medicine's MEAI compound, targeting metabolic syndrome and obesity. This application is part of an ongoing collaboration with Clearmind Medicine and Professor Joseph Tam from Hebrew University.The development addresses a significant market opportunity, as CDC data shows 41.9% of US adults aged 20 and over were obese during 2017-2020. The global obesity treatment market, valued at $15 billion in 2022, is projected to grow at a 10% CAGR, driven by increasing obesity prevalence and technological advancements.This marks the thirteenth patent application filed through the Clearmind collaboration, with previous applications covering treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders using the PEA-MEAI combination.